Recently, a groundbreaking oral drug for inflammatory bowel disease (IBD) has received a vital boost towards commercialization, thanks to specialized services provided by the Regional University-Industry Technology Transfer Center for Biopharmaceuticals (Suzhou, Jiangsu) in SIP.
The LT-1728-963, a first-in-class oral candidate developed by Prof. Chen Yadong’s team at China Pharmaceutical University, has demonstrated higher patient compliance, greater convenience and a stronger safety profile compared with existing therapies for the treatment of IBD.
The center lent the research team a hand in time when it was faced with a critical bottleneck in turning to market due to insufficient key validation data. Its POC (proof of concept) team carried out a comprehensive assessment to identify gaps in POC, analyzed market potential, and tailored the commercialization pathway for the project. The center also provided dedicated concept validation funding to support the team to conduct essential safety evaluations and downstream pathway verifications.
January 20, 2026
